Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adezmapimod + vimdemer
- Development stage
- Unknown
- Lead developer
- Pharmasyntez
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
Serogard (adezmapimod + vimdemer) is an innovative fixed-dose combination drug developed by the Irkutsk Scientific Center of Surgery and Traumatology and Pharmasyntez for the prevention and treatment of post-surgical adhesion formation. It consists of adezmapimod, a selective p38 mitogen-activated protein kinase (MAPK) inhibitor, and vimdemer, a polyvinylimidazole polyelectrolyte. The combination acts synergistically to suppress connective tissue growth and inflammatory responses in the zone of surgical intervention, thereby preventing the formation of peritoneal and other post-operative adhesions. Serogard is administered as an intraperitoneal solution during open or laparoscopic surgeries, primarily in abdominal surgery and gynecology, and is currently in Phase III clinical development.
- Brand names
- SerogardСерогард
- Other names
- Seroguardadezmapimod + vimdemeradezmapimod/vimdemerадезмапимод + вимдемерадезмапимод/вимдемер
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)GSK3 (Glycogen synthase kinase 3 beta)JNK (Mitogen-activated protein kinase kinase kinase family)LCK (Proto-oncogene tyrosine-protein kinase Lck)MK2 (Mitogen-activated protein kinase-activated protein kinase 2)PDK (Pyruvate dehydrogenase kinase isoform 1)RAF1 (c-Raf-1 (Y340D/Y341D))MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on adezmapimod + vimdemer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adezmapimod + vimdemer.